CureMatch

Our #ASCO25 paper Scoring approach 1st of kind predicting #clinicaltrial outcomes: lnkd.in/dpTSEvBs using #NGS +drug targeting profile, found patients who didn’t have prominent markers, YET did fairly well. For treatment planning & to qualify/quantify known+ novel drugs

In a world where #cancer treatment is no longer one-size-fits-all, CureMatch is transforming #precisiononcology with AI powered decision support. We analyzes each patient’s unique molecular tumor profile to deliver clear, ranked, and scored personalized treatment options.

@VivekSubbiah @MedCellPress @Dr_R_Kurzrock @DrChoueiri @montypal @PavlosMsaouel @PTarantinoMD At @CureMatch, we are honored to have the support of esteemed oncologists like Dr. @VivekSubbiah. This study he calls “Precision oncology’s E = MC 2” is the premise of CureMatch, founded by our very own @Dr_R_Kurzrock

🚨Hot off the press👉Pleased to share my new commentary: "Matching hallmarks of cancer complexity with N-of-1 precision oncology" 🧬 @MedCellPress 👉A viewpoint on the latest iteration of Doug Hanahan's Hallmarks of Cancer framework and @Dr_R_Kurzrock 's the i-PREDICT trial, and what they mean together for #precisionmedicine 👉What is #PrecisionOncology 's E=MC2 ? Tweetorial soon. @OncoAlert @MedwatchKate @OpenMedicineHQ @oncodaily @Aiims1742 @neerajaiims @weldeiry @chadinabhan Free @CellPressNews link for 50 days authors.elsevier.com/a/1mm2C9UKeTtQ…

Static molecular profiling (genomics, transcriptomics, etc.) gives great insights into a tumor’s biology and potential drug targets — but it doesn’t always predict if a treatment will actually work for that patient. That lab output is our input at @CureMatch

With the evolution of trial design, #oncology trials factor in precision, focusing on clinical outcomes, the impact of comprehensive #genomic profiling, and #clinicaltrial intelligence capabilities. The lab output is our input to assist pharma & CROs on patient stratification.

Glioblastoma (GBM), the most common primary malignant #braintumor, remains highly lethal, with median survival rarely exceeding 15 months. @CureMatch was used for a patient that is now over 5 years in remission! #precisiononcology @Dr_R_Kurzrock @illumina @GuardantHealth @CNN

#Cancer is not static: it’s a dynamic, evolving system. Tumor genomes are continually reshaped by the pressures of growth, immune attack, the local microenvironment—and above all by the selective force of #therapy. Ask for NGS lab work, which is our input for a @CureMatch report

Congratulations to our cofounder @Dr_R_Kurzrock and colleagues!

With #pancreaticcancer, oncogenic KRAS mutations are prevalent. However there are less common but therapeutically actionable alterations. Why true #precisiononcology would include #NGS lab work to determine the molecular makeup of each patients specific cancer. That is our input.

ascopubs.org/doi/pdfdirect/… “The field of rare cancer research is rapidly transforming, marked by significant progress in clinical trials and treatment strategies.” @Dr_R_Kurzrock @VivekSubbiah

The exponentially increasing oncology data from EHR, #radiology, #genomics, digital #pathology makes it even more critical to use tools like #AI to detect, treat and monitor better. It is beyond human cognition to process all the data and stay up to speed on new developments.

#Doctors, in our case #oncologists don’t have enough hours in the day. Between taking care of #patients and staying current on new advancements. Our report not only interprets the NGS lab work, but takes it significantly further with #clinical decision support. #AI @CNN @WSJ

Every individual #cancer patient has unique #biomarkers that can inform which precision #oncology treatments and therapies are appropriate and which are not.

#Immunotherapy has revolutionized therapy for head & neck #cancers, by helping to restore the immune system's cancer fighting capabilities. Not all patients respond so having specific #biomarkers can help identify patients who may benefit from immunotherapies. #precisiononcology

85% of lung cancer cases are non-small cell lung cancer, which is a leading cause of cancer mortality. With next-generation sequencing (NGS) then a #CureMatch report, there is increased identification of actionable oncogenic alterations. @illumina @ExactSciences @Dr_R_Kurzrock

@2StefanMoore We would love to synch up offline. If there is NGS lab work, that output is our input.

A deadly glioblastoma that’s long defied treatment just showed extraordinary responses in a Mass General trial that’s giving hope for #BrainCancer 🧠 Next-gen CAR-T therapy (dual-targeting EGFRvIII + wild-type EGFR) after one single infusion, all initial patients saw rapid tumor shrinkage, one nearly vanished, another ~60% reduction lasting months. Responses were temporary, but this proves a single dose can unleash powerful attacks on these tough tumors. Early days (phase 1 trial ongoing, more patients treated with promising safety), but a major step forward for immunotherapy in solid brain cancers. Source: Mass General / NEJM

While medicine has implemented trial-and-error strategies for discovering, developing, and testing new treatments, no two #cancers are ever molecularly the same. Truly personalized #precisionmedicine is catering to each specific patient’s disease as much as possible.

Precision medicine has greatly advanced #cancer research and clinical oncology with improved patient response. With next gen sequencing and then @CureMatch for clinical decision support, we highly recommend getting a second opinion as well before treatment starts.